Acquisition of own shares in the framework of employees’ long-term incentive plans

BRUSSELS, Belgium, 5 April 2011 – 19:30 (CET) – press release, regulated information - In application of art. 207 of the Royal Decree executing the Company Code, UCB publishes having acquired on the Brussels stock exchange on March 30, 2011: 33,827 shares at the price of EUR 27.1138 per share and on March 31, 2011: 84,528 shares at a price of EUR 26.9291 per share.

The shares were delivered to the employees benefiting from vestings of UCB’s stock award and performance share plans on April 1, 2011.

UCB S.A. - Allée de la Recherche, 60 - 1070 Bruxelles - RPM 0403.053.608

For further information
Antje Witte, Investor Relations, UCB
T +32.2.559.9414, antje.witte@ucb.com

Michael Tuck-Sherman, Investor Relations, UCB
T +32.2.559.9712, Michael.tuck-sherman@ucb.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

Forward-looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.